AUROPHARMA1,666.00

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹96,761 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation1,521.71,649.41,778.2
+ Impairment Loss / (Reversal)32.60.00.0
+ Finance Costs268.1440.4352.3
+ Interest Income-285.8-353.2-329.1
+ Dividend Income0.00.0-2.3
+ Fair Value (Gains) / Losses-2.716.90.0
+ Unrealised FX (Gain) / Loss-51.258.7221.0
+ Other Non-cash Items6.42.59.4
+ Other — Cash Effects are Investing / Financing0.00.054.6
+ Other Reconciling Items-10.1-12.10.0
Changes in Working Capital
+ Inventories-1,303.7-735.5-1,499.8
+ Trade Receivables — Current-264.2-862.1-1,170.7
+ Other Financial Assets — Current0.0-171.6155.6
+ Other Financial Assets — Non-current-173.60.00.0
+ Other Current Assets-669.0171.3-420.3
+ Trade Payables — Current582.8-310.91,281.6
+ Other Financial Liabilities — Current317.4936.81,057.2
+ Other Current Liabilities-263.4-331.5560.7
+ Provisions — Current98.659.0199.6
Cash from Operating Activities
Profit Before Tax (per I/S)4,397.25,098.05,110.35,422.1
+ Total Adjustments (incl. Working Capital)-196.0558.02,248.1
Cash from Operations (pre-tax)4,201.25,656.07,358.4
+ Income Taxes Paid1,766.61,731.41,832.0
Cash from Operating Activities2,434.53,924.65,526.4
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)2,780.31,967.92,685.8
+ Acq of Intangible Assets781.2551.7418.9
+ Disp of Fixed Assets60.32.846.3
+ Purchase of Investments (Equity / Debt)3.823.0787.8
+ Sale of Investments (Equity / Debt)179.2111.25.9
+ Acq of Interests in Joint Ventures21.90.00.0
+ Acq of Subsidiaries / Businesses (net)0.011.4303.2
+ Dividends Received — Investing0.00.02.3
+ Interest Received — Investing280.8347.4328.6
+ Other Inflows / (Outflows) — Investing-1,189.0217.4354.2
Cash from Investing Activities-4,256.0-1,875.1-3,458.4
Cash from Financing Activities
+ Buyback / Redemption of Own Shares0.0930.20.0
+ Payments — Change in Ownership of Subsidiaries0.022.50.0
+ Proceeds from Borrowings1,478.52,722.6719.9
+ Repayment of Borrowings17.21,118.91,304.0
+ Payment of Lease Liabilities146.6109.8108.5
+ Interest Paid250.7420.3344.1
+ Dividends Paid263.60.0232.4
+ Other Inflows / (Outflows) — Financing0.0-1.00.0
Cash from Financing Activities800.4119.8-1,269.2
Net Changes in Cash (pre-FX)-1,021.02,169.3798.8
+ Effect of FX Rate Changes on Cash14.29.1828.8
Net Changes in Cash-1,006.82,178.41,627.6
Closing Cash3,385.45,563.8
Reference Items
EBITDA5,843.06,582.86,845.77,085.3
EBITDA Margin %20.1520.7520.3420.28
Free Cash Flow (CFO − Capex)-1,127.01,405.12,421.72,421.7
Free Cash Flow to Equity2,611.21,812.1
Free Cash Flow per Basic Share-19.4024.1941.7041.70
Price to Free Cash Flow39.96
Cash Flow to Net Income0.771.131.58
Cash Paid for Taxes1,766.61,731.41,832.0
Cash Paid for Interest250.7420.3344.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.